The leadership transition at Fate Therapeutics is significant as it involves the retirement of a long-standing CEO, Scott Wolchko, and the appointment of Bob Valamehr. Such changes can influence the company's strategic direction and investor sentiment. However, since the transition is planned and announced well in advance, the immediate impact on stock price may be neutral unless further strategic changes are announced.